- Featured Product
- KD/KO Validated
MMP7 Polyclonal antibody
MMP7 Polyclonal Antibody for WB, IHC, IF/ICC, IF-P, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse and More (2)
Applications
WB, IHC, IF/ICC, IF-P, ELISA
Conjugate
Unconjugated
Cat no : 10374-2-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | A549 cells, human placenta tissue, SKOV-3 cells, NIH/3T3 cells, COLO 320 cells, PC-3 cells |
Positive IHC detected in | human pancreas cancer tissue, human prostate cancer tissue, human colon cancer tissue, human stomach cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Positive IF-P detected in | human pancreas cancer tissue |
Positive IF/ICC detected in | PC-3 cells |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:1000-1:4000 |
Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
KD/KO | See 2 publications below |
WB | See 74 publications below |
IHC | See 18 publications below |
IF | See 1 publications below |
Product Information
10374-2-AP targets MMP7 in WB, IHC, IF/ICC, IF-P, ELISA applications and shows reactivity with human, mouse samples.
Tested Reactivity | human, mouse |
Cited Reactivity | human, mouse, rat, pig |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | MMP7 fusion protein Ag0550 |
Full Name | matrix metallopeptidase 7 (matrilysin, uterine) |
Calculated Molecular Weight | 29 kDa |
Observed Molecular Weight | 28-30 kDa |
GenBank Accession Number | BC003635 |
Gene Symbol | MMP7 |
Gene ID (NCBI) | 4316 |
RRID | AB_2144452 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
Matrix metalloproteinase-7 (MMP-7)/ matrilysin is a member of the MMP family, but is structurally different from the other MMPs by virtue of the absence of a conserved COOH-terminal protein domain. MMPs are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and cancer metastasis. Most MMP's are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. MMP-7 degrades proteoglycans, fibronectin, elastin and casein, and is involved in wound healing, tumor progression, pulmonary fibrosis, and development of choroidal neovascularization in age-related macular degeneration. The expression of MMP-7 is increased in most tumors. This antibody can only recognize the full-length of MMP7.
Protocols
Product Specific Protocols | |
---|---|
WB protocol for MMP7 antibody 10374-2-AP | Download protocol |
IHC protocol for MMP7 antibody 10374-2-AP | Download protocol |
IF protocol for MMP7 antibody 10374-2-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Cancer Res Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kγ to promote pancreatic cancer metastasis. | ||
Cancer Res Ubiquitin-like protein FAT10 promotes the invasion and metastasis of hepatocellular carcinoma by modifying β-catenin degradation. | ||
Oncogene Transducin (β)-like 1 X-linked receptor 1 promotes gastric cancer progression via the ERK1/2 pathway. | ||
Clin Cancer Res BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs. | ||
Int J Cancer Modification of α2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway. |